Home/Pipeline/FabenCOV® (e-FabRIC)

FabenCOV® (e-FabRIC)

SARS-CoV-2 Infection

Phase 2Active

Key Facts

Indication

SARS-CoV-2 Infection

Phase

Phase 2

Status

Active

Company

Fabentech

About Fabentech

Founded in 2007, Fabentech is a private, clinical-stage biotech focused on biodefense and pandemic preparedness. Its core asset is the FabShield® platform for generating polyclonal antibody fragment therapies against lethal biological agents. The company has a diversified pipeline targeting toxins and viruses, with one product (Ricimed®) approved, another in Phase 2 for COVID-19, and several earlier-stage programs backed by European and French defense agencies. Fabentech operates as a specialized contractor for government and public health preparedness markets.

View full company profile

Therapeutic Areas

Infectious Disease Biotoxicity Bioterrorism Countermeasures

Other SARS-CoV-2 Infection Drugs

Drug	Company	Phase	Status
Talis One COVID-19 Test	Talis Biomedical	Commercial (EUA)	Terminated
Logix Smart COVID-19 Test	Co-Diagnostics	Commercial	Marketed
COV19 qcLAMP Kit	BIOPIX-T	Approved	Commercial (CE-IVD)
GenBody COVID-19 Ag Test	GenBody	Approved	Active
CovidDetect	Prime Discoveries	Commercial	Active
Favipiravir	Viriom	Bioequivalence	Active
EDP-323	Enanta Pharmaceuticals	Phase 1	Active
InteliSwab® COVID-19 Rapid Antigen Test	OraSure Technologies	Approved	Commercial